

Why use an allergy-based quality of life measure in childhood atopic eczema?

DOI: 10.1111/bjd.18157

Linked Article: Hon et al. *Br J Dermatol* 2019; **181**:290–295.

Atopic dermatitis (AD) does not exist in an isolated dermatological vacuum. Many patients have other allergic diseases as they march through their atopic destiny: for example, 60% of children with severe AD may develop asthma.¹ The summed impact of these coexisting conditions is what is of relevance to the patient (and their family), not the skin effects alone. To ensure a holistic assessment of our patients with AD, should we use a broad-based questionnaire?

The Paediatric Allergic Disease Quality of Life Questionnaire (PADQLQ) items were based on interviews with children with allergic asthma, rhinoconjunctivitis and/or eczema.² Its questions range over effects on the eyes, ears, nose, lungs, emotions and everyday activities, and also the skin. Validation was undertaken in children with systemic manifestations of grass pollen allergy, seasonal allergic rhinoconjunctivitis, asthma and/or eczema. In addition, all subjects had to have symptoms that developed during the pollen season and positive results for a skin prick test to grass pollens. Of the 25 questions, only 14 seem to be relevant to many children with atopic eczema. Remarkably, in view of these restricted origins, Hon et al.³ in this issue of the *BJD* have demonstrated good validation characteristics of PADQLQ in their patients with AD.

As might be expected, PADQLQ correlated better with another quality of life (QoL) measure, the Children's Dermatology Life Quality Index (CDLQI),⁴ than with the symptom/sign measures Patient Oriented Eczema Measure (POEM) and Nottingham Eczema Severity Score (NESS). One issue, important for many children, is that in contrast with the CDLQI, the PADQLQ does not contain items on bullying.⁵ However, it is reassuring that the PADQLQ scores in the domains 'practical', 'emotional' and 'symptoms' were greater in the patients with severe AD than in patients with 'mild-moderate' AD.³

Ways to measure dermatology-specific health-related QoL have mushroomed dramatically⁶ since the first childhood-specific measure in 1995.⁴ The major secondary burden of skin disease on families can now also be assessed.⁷ Although Rzany suggested that there are already too many QoL measures available for use in AD,⁸ PADQLQ does contribute a new specific perspective, as it extends the usual classification of QoL measures. It is neither a generic (all diseases) measure, disease-specific, nor a specialty-specific measure. Rather it is a 'cross-over' measure, covering allergic diseases. Perhaps one could envisage other hypothetical cross-over measures such as for 'autoimmune disease' or 'drug reactions'.

But what of the practical issues in using the PADQLQ? According to Hon et al.³ completion of the 25 questions takes 'less than 10 minutes', compared with 2 min to complete the 10-question CDLQI,⁹ an important consideration if a QoL measure is to be

used in routine busy clinical practice. Although score description bandings are available to give meaning to CDLQI scores, they do not exist for PADQLQ scores, limiting its clinical usefulness.

Why is this relevant to dermatologists who look after children with AD? The management of such children should consider their coexisting conditions, and some therapies may benefit more than one atopic condition. Some clinicians may not be aware of the extent of the combined impact of coexisting allergic disease on their patients.

Hon et al.³ have demonstrated 'reasonably good agreement' between the PADQLQ and the CDLQI, begging the question as to why another measure may be helpful. However, their work on the PADQLQ encourages us to view AD within a wider perspective and the measure may be useful in clinical research. But its value in routine dermatology practice remains at present untested.

Conflicts of interest

A.Y.F. is joint copyright owner of the CDLQI and T-QoL. Cardiff University and A.Y.F. receive royalties.

¹Dali Medical, Dermatology, Bucharest, Romania²Institute of Infection and Immunity, Cardiff University School of Medicine, Cardiff, U.K.

E-mail: lianamanolache@yahoo.com

L. MANOLACHE¹ 
A.Y. FINLAY² 

References

- 1 Han H, Roan F, Ziegler SF. The atopic march: current insights into skin barrier dysfunction and epithelial cell-derived cytokines. *Immunol Rev* 2017; **278**:116–30.
- 2 Roberts G, Hurley C, Lack G. Development of a quality-of-life assessment for the allergic child or teenager with multisystem allergic disease. *J Allergy Clin Immunol* 2003; **111**:491–7.
- 3 Hon KL, Ng WGG, Kung JSC et al. Utility of the Pediatric Allergic Disease Quality of Life Questionnaire for childhood eczema. *Br J Dermatol* 2019; **181**:290–95.
- 4 Lewis-Jones MS, Finlay AY. The Children's Dermatology Life Quality Index (CDLQI): initial validation and practical use. *Br J Dermatol* 1995; **132**:942–9.
- 5 Chernyshov PV. Stigmatization and self-perception in children with atopic dermatitis. *Clin Cosmet Investig Dermatol* 2016; **9**:159–66.
- 6 Chernyshov PV, Tomas-Aragones L, Manolache L et al. Quality of life measurement in atopic dermatitis. Position paper of the European Academy of Dermatology and Venereology (EADV) Task Force on quality of life. *J Eur Acad Dermatol Venereol* 2017; **31**:576–93.
- 7 Sampogna F, Finlay AY, Salek SS et al. Measuring the impact of dermatological conditions on family and caregivers: a review of dermatology-specific instruments. *J Eur Acad Dermatol Venereol* 2017; **31**:1429–39.

2 Commentary

- 8 Rzany B. Too many instruments for measuring quality of life in atopic dermatitis. *J Eur Acad Dermatol Venereol* 2017; **31**:574.
- 9 Holme SA, Man I, Sharpe SL et al. The Children's Dermatology Life Quality Index: validation of the cartoon version. *Br J Dermatol* 2003; **148**:285–90.

Supporting Information

Additional Supporting Information may be found in the online version of this article at the publisher's website:

Audio S1 Author audio.